The concern of generic competition has consistently loomed above copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the prospects of similar drug holdings. While first periods saw substantial profits, the patent lapse has allowed the way for cheaper alternatives, possibly lowering earnings and creating a significant hazard for